Qiagen said this week that it has signed an agreement with Eli Lilly to develop a companion diagnostic for an early-stage compound that Lilly is developing to treat blood cancer.

Specifically, Qiagen will develop an assay for the JAK2 V617F mutation that will identify patients likely to respond to the Lilly compound, which targets the Janus kinase 2 gene that has been shown to play a role in myeloproliferative neoplasms.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.